VSV/NDV hybrid virus for oncolytic therapy of cancer
Oncolytic virotherapy for cancer has emerged as a novel and promising therapeutic approach to replace standard cancer therapies, which often provide limited efficacy at the cost of unpleasant or severe side effects. Here, a novel VSV/NDV hybrid virus was engineered that combines the advantages of both vesicular stomatitis virus (VSV) and Newcastle disease virus (NDV) vectors, while the safety concerns of both are eliminated.
Further information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.
Media Contact
All latest news from the category: Technology Offerings
Newest articles
The future of digital agriculture
The Center for Digital Agriculture showcased the many advancements in digital agriculture during its annual conference. When the Center for Digital Agriculture (CDA) launched in 2018, they were looking forward…
Physicists arrange atoms in extremely close proximity
The technique opens possibilities for exploring exotic states of matter and building new quantum materials. Proximity is key for many quantum phenomena, as interactions between atoms are stronger when the…
For microscopic organisms, ocean currents act as ‘expressway’ to deeper depths
New research shows how tiny plant-like organisms hitch a ride on ocean currents to reach darker and deeper depths, where they impact carbon cycling and microbial dynamics in the subtropical…
